TEL AVIV, Israel, Nov. 07, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that management will participate in several upcoming investor healthcare conferences.
| Stifel Healthcare Conference | |
| Date: | Tuesday, November 15 |
| Time: | 4:30PM EST |
| Location: | The Lotte New York Palace Hotel |
| Jefferies London Healthcare Conference | |
| Date: | Thursday, November 17 |
| Time: | 09:20AM GMT |
| Location: | Waldorf Hilton, London, United Kingdom |
| Webcast: | http://wsw.com/webcast/jeff100/adhd |
| 28th Annual Piper Jaffray Healthcare Conference | |
| Date: | Tuesday, November 29 |
| Time: | 10:00AM EST |
| Panel Title: | Underdiscovered Neuro-Innovators Panel |
| Location: | The Lotte New York Palace Hotel |
| Oppenheimer Life Sciences Summit | |
| Date: | Tuesday, November 29 |
| Location: | The Sofitel New York Hotel |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX (Metadoxine Extended Release), a proprietary drug candidate to treat cognitive disorders including ADHD and Fragile X Syndrome. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
